The Phase 2 clinical trial results of a COVID-19 vaccine developed by Taiwan-based Medigen Vaccine Biologics Corp. generated good data, experts have said, but they cautioned there was still no way to know how effectively it will protect people against getting the disease.
(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)
Latest
- Politics
- Sports
Gymnastics chief dismissed after denying duo World spots
09/15/2026 09:25 PM - Politics
Labor minister stresses 'reciprocal dignity' ahead of China APEC meeting
09/15/2026 09:19 PM - Society
NT$1M reward offered for information leading to arrest of fugitive aide
09/15/2026 09:12 PM - Science & Tech
Taiwan study shows ongoing natural selection shaping disease susceptibility
09/15/2026 07:14 PM